Translate page

We are pleased to make available a couple of presentations that were first held during the EHA2022 Congress in Vienna. Presentations include; 'Non-BCR-ABL1 molecular biomarkers of prognosis in CML' and 'Mechanisms of disease progression in chronic myeloid leukemia'. 

Shady Awad 1

Non-BCR-ABL1 molecular biomarkers of prognosis in CML
Dr. Shady Awad, Hematology Research Unit Helsinki,
University of Helsinki (Finland)

  • Clinical heterogeneity and biomarkers in CML
  • Somatic mutations in CP-CML
  • Epigenetic modifier gene mutations in CP-CML
  • CHIP and clonal evolution in CP-CML
  • Somatic mutations in BP-CML
  • Fusion genes and rearrangements in CML
  • Gene expression signatures (GES) as prognosis markers
  • scRNA-sequencing in CML
  • RUNX1 as an example of mutation-induced GES in BP-CML
  • Molecular biomarkers of DMR
  • Epigenetic modifier gene mutations as a biomarker for TFR
  • Challenges and prospets

This talk was first presented during the  Scientific Working Group Session – ELN-EHA-SWG for CML: 'Understanding the pathogenesis of CML' at EHA 2022

Tiong Ong 1

Mechanisms of disease progression in chronic myeloid leukemia
Dr. S. Tiong Ong, Duke-NUS Medical School Singapore &
Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, NC, USA

Learning goals:

  • Understand that BP progression is characterized by a common, or 'core' transcriptome
  • Understand that polycomb complex (PCR-)-driven processes contribute to the 'core' transcriptome
  • Appreciate that a PCR-based model of CML progression identifies putative CP biomarkers
    and therapeutic strategies

This talk was first presented during the  Scientific Working Group Session – ELN-EHA-SWG for CML: 'Understanding the pathogenesis of CML' at EHA 2022

-- Virtual Education Program: 2019 Edition

 

Presentations from the COLT Meeting 2019

We are pleased to make available a series of presentations from the COLT Meeting 2019, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, management of CML, practicalities and monitoring TFR and Ph+ALL.


Timothy Hughes

David Yeung 3 Devendra Hiwase

Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • Frontline Therapy for CML 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)

 

 

Naranie

David Yeung 3 Susan Branford                    

Session 2: CML Management, Practicalities
Chair: Dr David Yeung

  • Managing TKI toxicities
    (Dr Naranie Shanmuganathan)
  • Allograft - still a role in CML?
    (Dr David Yeung)
  • Molecular monitoring
    (A/Prof Susan Branford)

 

 

Susan Branford

 

David Yeung 3                  

 

Session 3: Monitoring TFR and Ph+ ALL
Chair: Dr Naranie Shanmunagathan

  • Monitoring TFR - Challenges 
    (A/Prof Susan Branford)
  • Ph+ ALL
    (Dr David Yeung)